ONC BeOne Medicines Ltd.

NASDAQ
$346.51

BeOne Medicines Ltd. (ONC) Insider Activity

What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.

30D 90D 6M 1Y
Insider signal In line Selling ran in line with ONC's own trailing one-year pace, with 96% of sale value under a prearranged plan.
Cluster activity 0 buyers in the last 30 days 0 buyers in the last 90 days 7 sellers in the last 90 days
Insiders buying
0
0 transactions
Insiders selling
12
197 transactions
Purchases
$0
0 shares
Sales
$370.3M
1,154,178 shares
Net activity
-$370.3M
purchases less sales

How much of that selling was preplanned? 96% planned / 4% discretionary

10b5-1 plan sales $353.8M 140 transactions · 1,091,413 shares
Discretionary sales $16.5M 57 transactions · 62,765 shares

Largest single sale: $16.2M.

Where they traded

Buy Sell Dot area is proportional to transaction value.

No open-market insider purchase on record.

Recent open-market activity

Date Insider Role Action Shares Price Value Held after
Wang Xiaodong 8 fills Director Sell 10b5-1 38,287 $349.10 $13.4M 23,535 −61.9% of holding
Ball Titus B. Principal Accounting Officer Sell 132 $355.86 $47.0K None left
Wu Xiaobin President and COO Sell 10b5-1 280 $380.00 $106.4K None left
OYLER JOHN 5 fills Chief Executive Officer Sell 10b5-1 54,892 $358.15 $19.7M 52,912 −50.9% of holding
OYLER JOHN 9 fills Chief Executive Officer Sell 10b5-1 70,907 $361.90 $25.7M 112,104 −38.7% of holding
Lee Chan Henry SVP, General Counsel Sell 10b5-1 2,666 $360.00 $959.8K None left
OYLER JOHN 10 fills Chief Executive Officer Sell 10b5-1 115,011 $357.87 $41.2M 240,743 −32.3% of holding
Rosenberg Aaron Chief Financial Officer Sell 1,157 $312.72 $361.8K None left
Lee Chan Henry SVP, General Counsel Sell 1,044 $323.69 $337.9K None left
Lee Chan Henry SVP, General Counsel Sell 10b5-1 1,669 $325.00 $542.4K None left
OYLER JOHN 5 fills Chief Executive Officer Sell 10b5-1 61,397 $317.67 $19.5M 46,018 −57.2% of holding
OYLER JOHN 9 fills Chief Executive Officer Sell 10b5-1 48,316 $312.25 $15.1M 18,491 −72.3% of holding
OYLER JOHN 9 fills Chief Executive Officer Sell 10b5-1 64,628 $312.00 $20.2M 63,188 −50.6% of holding
OYLER JOHN 12 fills Chief Executive Officer Sell 10b5-1 166,597 $318.09 $53.0M 166,364 −50% of holding
OYLER JOHN 5 fills Chief Executive Officer Sell 10b5-1 116,557 $311.95 $36.4M 110,490 −51.3% of holding
OYLER JOHN 6 fills Chief Executive Officer Sell 10b5-1 145,861 $305.95 $44.6M 94,510 −60.7% of holding
OYLER JOHN 7 fills Chief Executive Officer Sell 10b5-1 48,520 $304.35 $14.8M 47,722 −50.4% of holding
OYLER JOHN 8 fills Chief Executive Officer Sell 10b5-1 11,698 $298.34 $3.5M 10,205 −53.4% of holding
Lee Chan Henry SVP, General Counsel Sell 10b5-1 664 $302.46 $200.8K None left
OYLER JOHN 3 fills Chief Executive Officer Sell 3,410 $273.78 $933.6K 1,610 −67.9% of holding
Wu Xiaobin President and COO Sell 1,292 $276.26 $356.9K None left
Wang Lai President, Global Head of R&D Sell 1,068 $276.74 $295.6K None left
OYLER JOHN 3 fills Chief Executive Officer Sell 3,693 $265.55 $980.7K 2,043 −64.4% of holding
Wu Xiaobin President and COO Sell 1,357 $266.76 $362.0K None left
Wang Lai President, Global Head of R&D Sell 1,169 $265.39 $310.2K None left
Lee Chan Henry SVP, General Counsel Sell 590 $265.98 $156.9K None left
OYLER JOHN 4 fills Chief Executive Officer Sell 1,949 $257.24 $501.4K 1,208 −61.7% of holding
Wang Lai President, Global Head of R&D Sell 756 $261.00 $197.3K None left
Wu Xiaobin President and COO Sell 626 $261.20 $163.5K None left
Rosenberg Aaron Chief Financial Officer Sell 631 $257.74 $162.6K None left
Lee Chan Henry SVP, General Counsel Sell 428 $257.63 $110.3K None left
Ball Titus B. 2 fills Principal Accounting Officer Sell 169 $257.20 $43.5K 120 −58.5% of holding
OYLER JOHN 2 fills Chief Executive Officer Sell 4,940 $270.56 $1.3M 1,120 −81.5% of holding
Wu Xiaobin 2 fills President and COO Sell 1,484 $269.37 $399.7K 40 −97.4% of holding
Wang Lai 2 fills President, Global Head of R&D Sell 1,367 $269.38 $368.2K 40 −97.2% of holding
Lee Chan Henry 2 fills SVP, General Counsel Sell 871 $270.42 $235.5K 160 −84.5% of holding
Ball Titus B. 2 fills Principal Accounting Officer Sell 136 $271.33 $36.9K 36 −79.1% of holding
Yi Qingqing Director Sell 235 $279.13 $65.6K None left
4 fills Sell 10,998 $23.82 $262.0K 145,326 −7% of holding
Dugan Margaret Director Sell 212 $309.60 $65.6K None left
Sanders Corazon (Corsee) D. Director Sell 212 $309.59 $65.6K None left
Riva Alessandro Director Sell 212 $309.51 $65.6K None left
Lee Chan Henry SVP, General Counsel Sell 10b5-1 332 $310.72 $103.2K None left
Lee Chan Henry SVP, General Counsel Sell 10b5-1 332 $311.59 $103.4K None left
Lee Chan Henry SVP, General Counsel Sell 10b5-1 341 $300.00 $102.3K None left
Lee Chan Henry 2 fills SVP, General Counsel Sell 10b5-1 1,660 $349.52 $580.2K 996 −62.5% of holding
Lee Chan Henry SVP, General Counsel Sell 10b5-1 664 $331.76 $220.3K None left
OYLER JOHN 10 fills Chief Executive Officer Sell 10b5-1 24,369 $302.87 $7.4M 22,492 −52% of holding
OYLER JOHN 14 fills Chief Executive Officer Sell 10b5-1 75,631 $307.79 $23.3M 98,209 −43.5% of holding
Lee Chan Henry SVP, General Counsel Sell 10b5-1 332 $325.00 $107.9K None left
Lee Chan Henry SVP, General Counsel Sell 10b5-1 332 $318.28 $105.7K None left
Sanders Corazon (Corsee) D. 2 fills Director Sell 2,627 $340.90 $895.5K 804 −76.6% of holding
Wu Xiaobin 3 fills President and COO Sell 3,991 $380.43 $1.5M 836 −82.7% of holding
Wu Xiaobin 2 fills President and COO Sell 6,009 $380.54 $2.3M 1,769 −77.3% of holding
Wu Xiaobin 8 fills President and COO Sell 10,000 $356.02 $3.6M 15,509 −39.2% of holding
Lee Chan Henry 2 fills SVP, General Counsel Sell 10b5-1 996 $349.17 $347.8K 332 −75% of holding
Lee Chan Henry 4 fills SVP, General Counsel Sell 10b5-1 10,671 $350.40 $3.7M 8,895 −54.5% of holding
OYLER JOHN 5 fills Chief Executive Officer Sell 10b5-1 27,803 $325.71 $9.1M 23,737 −53.9% of holding

Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.